Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 567

1.

Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS.

Fox EJ, Lublin FD, Wolinsky JS, Cohen JA, Williams IM, Meng X, Ziehn M, Kolodny S, Cree BAC.

Neurol Neuroimmunol Neuroinflamm. 2019 Sep 11;6(6). pii: e614. doi: 10.1212/NXI.0000000000000614. Print 2019 Nov.

2.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators.

Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30238-8. doi: 10.1016/S1474-4422(19)30238-8. [Epub ahead of print]

PMID:
31492652
3.

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators.

Lancet Neurol. 2019 Sep 3. pii: S1474-4422(19)30239-X. doi: 10.1016/S1474-4422(19)30239-X. [Epub ahead of print]

PMID:
31492651
4.

A comparison of post-procedural anticoagulation in high-risk patients undergoing WATCHMAN device implantation.

Cohen JA, Heist EK, Galvin J, Lee H, Johnson M, Fitzsimons M, Slattery K, Ghoshhajra B, Sakhuja R, Ha G, Forsch M, Shi L, Danik J, Dal-Bianco J, Sanborn D, Hung J, Ruskin J, Gurol ME, Mansour M.

Pacing Clin Electrophysiol. 2019 Sep 3. doi: 10.1111/pace.13796. [Epub ahead of print]

PMID:
31479160
5.

Two Unusual Cases of Discoid Lupus Erythematosus Associated With Xanthomatized Macrophages.

Weiss A, Kwon EJ, Kreidel M, Mann R, Cohen JA, Hui Y, Jacobson MI.

Am J Dermatopathol. 2019 Aug 20. doi: 10.1097/DAD.0000000000001510. [Epub ahead of print]

PMID:
31464721
6.

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.

Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, McKechnie S, Han MH, Tomczak AJ, Levy M, Mealy MA, Coleman J, Bennett JL, Johnson R, Barnes-Garcia M, Traboulsee AL, Carruthers RL, Lee LE, Schubert JJ, McMullen K, Kister I, Rimler Z, Reid A, Sicotte NL, Planchon SM, Cohen JA, Ivancic D, Sedlak JL, Sand IK, Repovic P, Amezcua L, Pruitt A, Amundson E, Chitnis T, Mullin DS, Klawiter EC, Russo AW, Riley CS, Onomichi KB, Levine L, Nelson KE, Nealon NM, Engel C, Kruse-Hoyer M, Marcille M, Tornes L, Rumpf A, Greer A, Kenneally Behne M, Rodriguez RR, Behne DW, Blackway DW, Coords B, Blaschke TF, Sheard J, Smith TJ, Behne JM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF–ICC).

Neurol Neuroimmunol Neuroinflamm. 2019 Jun 28;6(5). pii: e583. doi: 10.1212/NXI.0000000000000583. Print 2019 Sep.

7.

Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.

McGinley MP, Cola PA, Fox RJ, Cohen JA, Corboy JJ, Miller D.

Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314. [Epub ahead of print]

PMID:
31368401
8.

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.

Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, McKechnie S, Han MH, Tomczak AJ, Levy M, Mealy MA, Coleman J, Bennett JL, Johnson R, Barnes-Garcia M, Traboulsee AL, Carruthers RL, Lee LE, Schubert JJ, McMullen K, Kister I, Rimler Z, Reid A, Sicotte NL, Planchon SM, Cohen JA, Ivancic D, Sedlak JL, Sand IK, Repovic P, Amezcua L, Pruitt A, Amundson E, Chitnis T, Mullin DS, Klawiter EC, Russo AW, Riley CS, Onomichi KB, Levine L, Nelson KE, Nealon NM, Engel C, Kruse-Hoyer M, Marcille M, Tornes L, Rumpf A, Greer A, Kenneally Behne M, Rodriguez RR, Behne DW, Blackway DW, Coords B, Blaschke TF, Sheard J, Smith TJ, Behne JM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF–ICC).

Neurol Neuroimmunol Neuroinflamm. 2019 Jun 28;6(5):e583. doi: 10.1212/NXI.0000000000000583. eCollection 2019 Sep.

9.

Cutaneous TRPV1+ Neurons Trigger Protective Innate Type 17 Anticipatory Immunity.

Cohen JA, Edwards TN, Liu AW, Hirai T, Jones MR, Wu J, Li Y, Zhang S, Ho J, Davis BM, Albers KM, Kaplan DH.

Cell. 2019 Aug 8;178(4):919-932.e14. doi: 10.1016/j.cell.2019.06.022. Epub 2019 Jul 25.

PMID:
31353219
10.

MRI Volume Changes of Axillary Lymph Nodes as Predictor of Pathologic Complete Responses to Neoadjuvant Chemotherapy in Breast Cancer.

Cattell RF, Kang JJ, Ren T, Huang PB, Muttreja A, Dacosta S, Li H, Baer L, Clouston S, Palermo R, Fisher P, Bernstein C, Cohen JA, Duong TQ.

Clin Breast Cancer. 2019 Jun 26. pii: S1526-8209(19)30037-0. doi: 10.1016/j.clbc.2019.06.006. [Epub ahead of print]

PMID:
31327729
11.

Survivorship Wellness: Insights from an Interdisciplinary Group-Based Survivorship Pilot Program at a Comprehensive Cancer Center.

Cohen JA, Shumay DM, Chesney MA, Goyal N, Barulich M, Levin AO.

J Altern Complement Med. 2019 Jul;25(7):678-680. doi: 10.1089/acm.2019.0080. No abstract available.

PMID:
31314557
12.

Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Feng J, Offerman E, Lin J, Fisher E, Planchon SM, Sakaie K, Lowe M, Nakamura K, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2019 Jun 14;5(2):2055217319856035. doi: 10.1177/2055217319856035. eCollection 2019 Apr-Jun.

13.

Sex Differences in Patient Characteristics, Treatment Strategies, and Outcomes for Type 2 Myocardial Infarction.

McCarthy CP, Murphy S, Cohen JA, Rehman S, Jones-O'Connor M, Olshan DS, Singh A, Vaduganathan M, Januzzi JL Jr, Wasfy JH.

J Am Coll Cardiol. 2019 Jun 25;73(24):3230-3232. doi: 10.1016/j.jacc.2019.04.016. No abstract available.

PMID:
31221266
14.

Developing therapeutic strategies to promote myelin repair in multiple sclerosis.

Baldassari LE, Feng J, Clayton BLL, Oh SH, Sakaie K, Tesar PJ, Wang Y, Cohen JA.

Expert Rev Neurother. 2019 Jun 20:1-17. doi: 10.1080/14737175.2019.1632192. [Epub ahead of print]

PMID:
31215271
15.

Longitudinal changes in brain function associated with symptom improvement in youth with PTSD.

Garrett A, Cohen JA, Zack S, Carrion V, Jo B, Blader J, Rodriguez A, Vanasse TJ, Reiss AL, Agras WS.

J Psychiatr Res. 2019 Jul;114:161-169. doi: 10.1016/j.jpsychires.2019.04.021. Epub 2019 Apr 27.

PMID:
31082658
16.

Depression in Maltreated Children and Adolescents.

De Bellis MD, Nooner KB, Scheid JM, Cohen JA.

Child Adolesc Psychiatr Clin N Am. 2019 Jul;28(3):289-302. doi: 10.1016/j.chc.2019.02.002. Epub 2019 Apr 4. Review.

PMID:
31076108
17.

The emergence of follow-on disease-modifying therapies for multiple sclerosis.

Moss BP, Cohen JA.

Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106. [Epub ahead of print]

PMID:
31074707
18.

Trauma-Focused Cognitive Behavioral Therapy for Childhood Traumatic Separation.

Cohen JA, Mannarino AP.

Child Abuse Negl. 2019 Jun;92:179-195. doi: 10.1016/j.chiabu.2019.03.006. Epub 2019 Apr 15.

PMID:
30999167
19.

Misclassification of Myocardial Injury as Myocardial Infarction: Implications for Assessing Outcomes in Value-Based Programs.

McCarthy C, Murphy S, Cohen JA, Rehman S, Jones-O'Connor M, Olshan DS, Singh A, Vaduganathan M, Januzzi JL Jr, Wasfy JH.

JAMA Cardiol. 2019 May 1;4(5):460-464. doi: 10.1001/jamacardio.2019.0716.

PMID:
30879022
20.

Movement disorders in early MS and related diseases: A prospective observational study.

Abboud H, Yu XX, Knusel K, Fernandez HH, Cohen JA.

Neurol Clin Pract. 2019 Feb;9(1):24-31. doi: 10.1212/CPJ.0000000000000560.

PMID:
30859004
21.

Underutilization of Cardiac Rehabilitation for Type 2 Myocardial Infarction.

McCarthy CP, Murphy S, Cohen JA, Rehman S, Jones-O'Connor M, Olshan DS, Singh A, Vaduganathan M, Januzzi JL Jr, Wasfy JH.

J Am Coll Cardiol. 2019 Apr 23;73(15):2005-2007. doi: 10.1016/j.jacc.2019.01.032. Epub 2019 Mar 4. No abstract available.

PMID:
30846342
22.

Pilot Evaluation of a Tablet-Based Application to Improve Quality of Care in Child Mental Health Treatment.

Davidson TM, Bunnell BE, Saunders BE, Hanson RF, Danielson CK, Cook D, Chu BC, Dorsey S, Adams ZW, Andrews AR 3rd, Walker JH, Soltis KE, Cohen JA, Deblinger E, Ruggiero KJ.

Behav Ther. 2019 Mar;50(2):367-379. doi: 10.1016/j.beth.2018.07.005. Epub 2018 Jul 27.

23.

Knowledge of radiation legislation and guidelines amongst foundation doctors is inadequate for safe practice in the current era of radiology.

Cohen JA.

Clin Radiol. 2019 Jun;74(6):418-420. doi: 10.1016/j.crad.2019.01.020. Epub 2019 Feb 23. Review.

PMID:
30803812
24.

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE.

Biol Blood Marrow Transplant. 2019 May;25(5):845-854. doi: 10.1016/j.bbmt.2019.02.014. Epub 2019 Feb 19. Review.

25.

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.

Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.

Lancet Neurol. 2019 Feb;18(2):185-197. doi: 10.1016/S1474-4422(18)30460-5. Review.

PMID:
30663608
26.

The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod.

Cohen JA, Bar-Or A, Cree BAC, Mao-Draayer Y, Han MH, Singer B, Jannu A, Kolodny S, Meng X, Winger RC.

Mult Scler J Exp Transl Clin. 2019 Jan 2;5(1):2055217318819245. doi: 10.1177/2055217318819245. eCollection 2019 Jan-Mar.

27.

Follow-on glatiramer acetate.

Cohen JA, Wolf C, Selmaj K, Arends R.

eNeurologicalSci. 2018 Nov 23;13:51-52. doi: 10.1016/j.ensci.2018.11.019. eCollection 2018 Dec. No abstract available.

28.

Polygenic adaptation and convergent evolution on growth and cardiac genetic pathways in African and Asian rainforest hunter-gatherers.

Bergey CM, Lopez M, Harrison GF, Patin E, Cohen JA, Quintana-Murci L, Barreiro LB, Perry GH.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11256-E11263. doi: 10.1073/pnas.1812135115. Epub 2018 Nov 9.

29.

Genetic findings in adolescent and adult-onset leukodystrophies with hypomyelinating features.

Macaron G, Samaan S, Cohen JA, Nadjar Y.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):836-838. doi: 10.1136/jnnp-2018-319214. Epub 2018 Nov 2. No abstract available.

PMID:
30389777
30.

Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.

Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, Hudson LD, Rudick RA, LaRocca NG; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204. [Epub ahead of print]

PMID:
30334474
31.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
32.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487.

33.

Helping Children With Traumatic Reactions to Parental Suicide.

Cohen JA, Mannarino AP.

J Am Acad Child Adolesc Psychiatry. 2018 Aug;57(8):619. doi: 10.1016/j.jaac.2018.05.009.

PMID:
30071985
34.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2019 Aug;25(9):1255-1262. doi: 10.1177/1352458518789884. Epub 2018 Jul 25.

35.

Integrating multiple sclerosis guidelines into practice.

Macaron G, Cohen JA.

Lancet Neurol. 2018 Aug;17(8):658-660. doi: 10.1016/S1474-4422(18)30248-5. Epub 2018 Jul 17. No abstract available.

PMID:
30033052
36.

Applying the 2017 McDonald diagnostic criteria for multiple sclerosis - Authors' reply.

Thompson AJ, Reingold SC, Cohen JA; International Panel on Diagnosis of Multiple Sclerosis.

Lancet Neurol. 2018 Jun;17(6):499-500. doi: 10.1016/S1474-4422(18)30168-6. No abstract available.

PMID:
29778360
37.

Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis.

Planchon SM, Lingas KT, Reese Koç J, Hooper BM, Maitra B, Fox RM, Imrey PB, Drake KM, Aldred MA, Lazarus HM, Cohen JA.

Mult Scler J Exp Transl Clin. 2018 Mar 26;4(1):2055217318765288. doi: 10.1177/2055217318765288. eCollection 2018 Jan-Mar.

38.

Neuromuscular diseases associated with Human Immunodeficiency Virus infection.

Prior DE, Song N, Cohen JA.

J Neurol Sci. 2018 Apr 15;387:27-36. doi: 10.1016/j.jns.2018.01.016. Epub 2018 Jan 31. Review.

PMID:
29571868
39.

Being in-between: A model of cultural identity negotiation for emerging adult immigrants.

Cohen JA, Kassan A.

J Couns Psychol. 2018 Mar;65(2):133-154. doi: 10.1037/cou0000265.

PMID:
29543472
40.

Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations.

Baldassari LE, Cohen JA.

EBioMedicine. 2018 Mar;29:5-6. doi: 10.1016/j.ebiom.2018.02.021. Epub 2018 Feb 23. No abstract available.

41.

Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.

Cohen JA, Hunter SF, Brown TR, Gudesblatt M, Thrower BW, Llorens L, Souza-Prien CJ, Ruby AE, Chernoff DN, Patni R.

Mult Scler. 2019 Apr;25(4):601-609. doi: 10.1177/1352458518754716. Epub 2018 Jan 25.

PMID:
29368539
42.
43.
44.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
45.

Adjunctive Therapies for Catheter Ablation of Non-Paroxysmal Atrial Fibrillation.

Cohen JA, Mansour M.

J Atr Fibrillation. 2016 Dec 31;9(4):1490. doi: 10.4022/jafib.1490. eCollection 2016 Dec. Review.

46.

Comorbidities in MS are associated with treatment intolerance and disability.

McDonnell GV, Cohen JA.

Neurology. 2017 Nov 28;89(22):2218-2219. doi: 10.1212/WNL.0000000000004699. Epub 2017 Nov 1. No abstract available.

PMID:
29093072
47.

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Havrdova E, Cohen JA, Horakova D, Kovarova I, Meluzinova E.

Ther Clin Risk Manag. 2017 Oct 16;13:1423-1437. doi: 10.2147/TCRM.S143509. eCollection 2017. Review.

48.

Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study.

Pomeraniec IJ, Kano H, Xu Z, Nguyen B, Siddiqui ZA, Silva D, Sharma M, Radwan H, Cohen JA, Dallapiazza RF, Iorio-Morin C, Wolf A, Jane JA, Grills IS, Mathieu D, Kondziolka D, Lee CC, Wu CC, Cifarelli CP, Chytka T, Barnett GH, Lunsford LD, Sheehan JP.

J Neurosurg. 2018 Sep;129(3):648-657. doi: 10.3171/2017.5.JNS163069. Epub 2017 Oct 27.

49.

Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.

Mahajan KR, Ko JS, Tetzlaff MT, Hudgens CW, Billings SD, Cohen JA.

Mult Scler Relat Disord. 2017 Oct;17:12-14. doi: 10.1016/j.msard.2017.06.004. Epub 2017 Jun 22.

PMID:
29055440
50.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

Supplemental Content

Loading ...
Support Center